Efficacy and safety of controlled ovarian hyperstimulation with or without letrozole for fertility preservation in breast cancer patients: A multicenter retrospective study

Goldrat, Oranite; Cooman, Manon De; Mailliez, Audrey; Delbaere, Anne; D'Orazio, Emmanuelle; Demeestere, Isabelle; Decanter, Christine

doi:10.1016/j.ejca.2022.07.017

Cited by 5 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The present study included samples from mixed COS protocols (agonist and an-tagonist), as well as mixed ovulation triggering methods. Unfortunately, the number of patients in this study was not large enough to sub-divide the AI group by the COS protocol or trigger method 19) . Further accumulation of cases will be necessary in the future.…”

Section: Discussionmentioning

confidence: 97%

Effects of Follicular Testosterone on Cumulus and Granulosa Cells during Ovarian Stimulation with Aromatase Inhibitors in Patients with Breast Cancer

Mima

Sugishita

Meng

et al. 2022

J St. Marianna Univ

View full text Add to dashboard Cite

For patients with estrogen-sensitive tumors, there is a concern that the high estrogen state induced by controlled ovarian stimulation (COS) for oocyte retrieval may stimulate the growth of cancer cells. Protocols using aromatase inhibitors (AIs) have been developed to suppress the elevated estrogen levels during ovarian stimulation. However, studies have shown that COS with AI may induce apoptosis in cumulus and granulosa cells due to an increase in the androgen/estrogen ratio, which is associated with decreased oocyte quality. In the present study, we examined the hormonal dynamics in follicular fluid collected from patients with breast cancers who underwent COS with AI for fertility preservation (n = 11). In addition, we examined the relative gene expressions of several oocyte quality predictor genes in the cumulus and granulosa cells. The control samples were collected from patients with general infertility who underwent COS without AI (n = 17). Methods: The study population included patients with breast cancer who underwent COS with AI for oocyte retrieval for fertility preservation (n = 11, AI group) and patients with general infertility who underwent COS without AI for oocyte retrieval for in vitro fertilization (IVF) (n = 17, control group). The follicular fluid was collected at the time of oocyte retrieval. Estradiol (E2), progesterone, testosterone, and anti-Müllerian hormone (AMH) levels in the follicular fluid were measured by enzyme-linked immunosorbent assay (ELISA), and relative gene expressions of bone morphogenetic protein 3 (BMP3), prostaglandin-endoperoxide synthase 2 (PTGS2) and hyaluronan synthase 2 (HAS2) were analyzed by quantitative real-time polymerase chain reaction (qRT-PCR). Results: Compared to the control group, the levels of E2 were significantly suppressed while the testosterone and AMH levels increased in the AI group. No significant differences were observed in the progesterone levels. The relative gene expressions of BMP3, PTGS2 and HAS2 in cumulus and granulosa cells showed no significant differences between the two groups. Conclusion:We confirmed that COS with AI suppressed the E2 levels in the follicular fluid of patients with breast cancer. The elevated testosterone level in follicular fluid did not alter the BMP3, PTGS2 and HAS2 gene expressions in cumulus and granulosa cells nor affect the number of oocytes retrieved.

show abstract

Section: Discussionmentioning

confidence: 97%

Effects of Follicular Testosterone on Cumulus and Granulosa Cells during Ovarian Stimulation with Aromatase Inhibitors in Patients with Breast Cancer

Mima

Sugishita

Meng

et al. 2022

J St. Marianna Univ

View full text Add to dashboard Cite

show abstract

“…Bei Patientinnen mit Hormonrezeptorpositivem Mammakarzinom sollte nach derzeitigem Kenntnisstand ein Stimulationsprotokoll mit dem Aromatasehemmer Letrozol angewandt werden, um die Östrogenspiegel niedrig zu halten. Es hat sich gezeigt, dass die Spiegel um etwa ein Drittel niedriger sind [11]. In zwei unterschiedlichen Studien war die Anzahl der gewonnenen Eizellen mit und ohne Letrozolgabe vergleichbar [11,12].…”

unclassified

“…Es hat sich gezeigt, dass die Spiegel um etwa ein Drittel niedriger sind [11]. In zwei unterschiedlichen Studien war die Anzahl der gewonnenen Eizellen mit und ohne Letrozolgabe vergleichbar [11,12]. Die Anzahl der Überstimulationssyndrome unterschied sich nicht.…”

unclassified

Fertilitätserhalt – State of the Art in Österreich

Böttcher

2023

J. Gynäkol. Endokrinol. AT

View full text Add to dashboard Cite

ZusammenfassungEs ist essenziell, Frauen und Männer vor einer gonadotoxischen Therapie über mögliche fertilitätsprotektive Maßnahmen aufzuklären und diese anzubieten. Eine frühzeitige Vorstellung seitens der Onkolog:innen kann den Patientinnen Bedenkzeit und eine bessere Planung der Maßnahmen ermöglichen. Zunehmend stellen auch benigne Erkrankungen mit erforderlicher gonadotoxischer Therapie oder genetische Prädispositionen mit einem erhöhten Risiko für eine prämature Ovarialinsuffizienz eine Indikation für fertilitätserhaltende Maßnahmen dar. Für diese Thematik sollte interdisziplinär sensibilisiert werden, um diese Patientinnen frühzeitig zu identifizieren. Eine einheitliche Regelung der Kosten und der Kostenübernahme für fertilitätsprotektive Maßnahmen für Frauen und Männer sollte im Sinne der Patient:innen baldmöglichst angestrebt werden.

show abstract